Pfizer and BioNTech were the first producers of vaccines to draw.
Two weeks after the identification of the Omicron variant, the American laboratory and its German ally indicated on Wednesday that their vaccine was "
still effective
" after "
three doses
" against this new variant.
This is the result of preliminary studies carried out in laboratories by the two companies.
It is at this stage impossible to know the precise rate of effectiveness of the vaccine in the absence of dedicated clinical trials.
However, it is known that "
a third dose provides a level of neutralizing antibodies against Omicron similar to that observed after two doses
" against the other variants.
Two scenarios
This does not prevent Pfizer / BioNTech - which will have produced 3 billion doses this year - from working on a new formulation of its vaccine specifically adapted to Omicron.
The two labs hope to make it available by March.
This new version could be favored by the health authorities to increase the
This article is for subscribers only.
You have 82% left to discover.
Pushing back the limits of science is also freedom.
Continue reading your article for € 1 the first month
I ENJOY IT
Already subscribed?
Log in
